Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of iptacopan versus placebo in primary IgA nephropathy
NL-OMON60768Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Iptacopan with Placebo (2 arms). Primary endpoints: Log-transformed ratio to baseline in UPCR at 9 months and Annualized total eGFR slope over 24 months. Started Jul 2021; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON60768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60768.